Biogen Inc. $BIIB Shares Acquired by Hills Bank & Trust Co

Hills Bank & Trust Co grew its position in Biogen Inc. (NASDAQ:BIIB) by 17.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,586 shares of the biotechnology company’s stock after purchasing an additional 829 shares during the period. Hills Bank & Trust Co’s holdings in Biogen were worth $702,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Generali Investments CEE investicni spolecnost a.s. lifted its position in Biogen by 43.2% during the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 38,755 shares of the biotechnology company’s stock worth $4,867,000 after acquiring an additional 11,695 shares in the last quarter. Privium Fund Management B.V. acquired a new position in Biogen during the 2nd quarter worth approximately $2,666,000. Nordea Investment Management AB lifted its position in Biogen by 5.7% during the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after acquiring an additional 6,811 shares in the last quarter. Point72 Europe London LLP acquired a new position in Biogen during the 1st quarter worth approximately $11,286,000. Finally, Motley Fool Asset Management LLC lifted its position in Biogen by 64.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 6,809 shares of the biotechnology company’s stock worth $932,000 after acquiring an additional 2,676 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BIIB. Wedbush upped their target price on Biogen from $135.00 to $143.00 and gave the company a “neutral” rating in a research report on Friday. Truist Financial began coverage on Biogen in a research report on Monday, July 21st. They issued a “hold” rating and a $142.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Biogen in a research report on Wednesday, September 24th. Guggenheim upped their target price on Biogen from $165.00 to $185.00 in a research report on Friday. Finally, Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research report on Wednesday, September 24th. Nine analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. According to data from MarketBeat.com, Biogen has a consensus rating of “Hold” and a consensus price target of $177.00.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $154.27 on Friday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $179.48. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $22.62 billion, a price-to-earnings ratio of 14.75, a price-to-earnings-growth ratio of 1.17 and a beta of 0.13. The business has a 50 day simple moving average of $144.21 and a 200-day simple moving average of $133.65.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business had revenue of $2.53 billion during the quarter, compared to the consensus estimate of $2.34 billion. During the same period in the previous year, the business earned $4.08 EPS. The business’s quarterly revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 517 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the completion of the sale, the insider directly owned 5,772 shares in the company, valued at approximately $770,850.60. The trade was a 8.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.